Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study
| Autor: | Paola Piccini, David J. Brooks, Lorenzo Kiferle, Kit Wu, Marios Politis, Clare Loane, Sophie Molloy |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Benzylamines Serotonin Parkinson's disease Serotonergic DASB Sensitivity and Specificity Severity of Illness Index lcsh:RC321-571 chemistry.chemical_compound Predictive Value of Tests Internal medicine Severity of illness medicine Humans Carbon Radioisotopes Parkinson lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry Serotonin transporter Aged biology Dopaminergic Parkinson Disease Human brain Middle Aged medicine.disease medicine.anatomical_structure Endocrinology PET Neurology chemistry Positron-Emission Tomography biology.protein Female Psychology Neuroscience |
| Zdroj: | Neurobiology of Disease, Vol 40, Iss 1, Pp 216-221 (2010) |
| Popis: | Thirty Parkinson's disease (PD) patients were divided into three equal groups according to their disease duration while 10 normal healthy volunteers matched for age and sex served as a control group. Striatal and extrastriatal serotonergic function was studied with (11)C-DASB PET, a marker of serotonin transporter availability. (11)C-DASB binding was correlated with disease disability and exposure to dopaminergic therapy. We found significant (11)C-DASB binding reductions in striatal, brainstem, and cortical regions in PD but no correlations were evident between (11)C-DASB binding and UPDRS scores, Hoehn &Yahr staging, disease duration and level of exposure to dopaminergic therapy. Our results suggest that progressive non-linear serotonergic dysfunction occurs in PD but it does not determine levels of disability. Additionally, chronic exposure to dopaminergic therapy does not appear to influence SERT binding. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|